Bosun Asset Management LLC Acquires New Position in Protagonist Therapeutics, Inc. $PTGX

Bosun Asset Management LLC bought a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 10,226 shares of the company’s stock, valued at approximately $565,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Guggenheim Capital LLC boosted its position in Protagonist Therapeutics by 1.6% during the second quarter. Guggenheim Capital LLC now owns 19,208 shares of the company’s stock worth $1,062,000 after acquiring an additional 303 shares during the last quarter. Bessemer Group Inc. boosted its holdings in shares of Protagonist Therapeutics by 171.0% during the second quarter. Bessemer Group Inc. now owns 504 shares of the company’s stock worth $28,000 after purchasing an additional 318 shares during the last quarter. Hsbc Holdings PLC boosted its holdings in shares of Protagonist Therapeutics by 4.1% during the first quarter. Hsbc Holdings PLC now owns 8,458 shares of the company’s stock worth $405,000 after purchasing an additional 330 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Protagonist Therapeutics by 16.6% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,394 shares of the company’s stock valued at $132,000 after purchasing an additional 340 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Protagonist Therapeutics by 0.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,403 shares of the company’s stock valued at $1,810,000 after purchasing an additional 348 shares during the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Citigroup lifted their price target on Protagonist Therapeutics from $96.00 to $98.00 and gave the company a “buy” rating in a report on Monday, November 10th. Leerink Partners assumed coverage on shares of Protagonist Therapeutics in a report on Friday, September 12th. They issued an “outperform” rating and a $73.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Protagonist Therapeutics in a research note on Wednesday, October 8th. Johnson Rice set a $112.00 price target on shares of Protagonist Therapeutics in a report on Monday, October 13th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Protagonist Therapeutics from $68.00 to $81.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Protagonist Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $82.23.

Insider Activity at Protagonist Therapeutics

In other Protagonist Therapeutics news, Director William D. Waddill sold 12,000 shares of Protagonist Therapeutics stock in a transaction on Friday, October 10th. The stock was sold at an average price of $81.62, for a total transaction of $979,440.00. Following the sale, the director owned 5,130 shares of the company’s stock, valued at $418,710.60. The trade was a 70.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.90% of the company’s stock.

Protagonist Therapeutics Stock Up 2.7%

Shares of NASDAQ PTGX opened at $89.65 on Friday. The business has a 50 day moving average price of $78.77 and a two-hundred day moving average price of $63.39. Protagonist Therapeutics, Inc. has a fifty-two week low of $33.70 and a fifty-two week high of $93.25. The firm has a market cap of $5.60 billion, a PE ratio of 144.60 and a beta of 2.19.

Protagonist Therapeutics (NASDAQ:PTGX) last released its earnings results on Thursday, November 6th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.03). Protagonist Therapeutics had a return on equity of 6.86% and a net margin of 21.94%.The company had revenue of $4.71 million during the quarter, compared to the consensus estimate of $5.41 million. On average, analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.